DuPont’s clinical study shows more health benefits from higher doses of multi-strain probiotics

USA – DuPont, the world’s leading science-based products and services company has released clinical study results demonstrating benefits of high-potency, multi-strain probiotic formulations.

The study suggests that higher doses of a DuPont Multispecies Probiotic Formulation may permit more benefits for healthy adults than lower doses.

According to a clinical trial carried out in collaboration with the University of Milan (IT), ingesting higher doses of multispecies probiotic formulations may permit higher, earlier and longer recovery of probiotics in feces of healthy adults.

The study investigated the effect of bacterial count on the transient colonization in the human intestinal tract of four different DuPont probiotic strains including Bifidobacterium lactis Bl-04®, Lactobacillus acidophilus La-14®, Lactobacillus plantarum SDZ-11 and Lactobacillus paracasei SDZ-22.

ADVERT

The study found the first day of detection of the four probiotic strains was earlier in the high dose group when compared to that of the low dose group.

During the follow-up period, viable recovery was significantly higher and detectable longer in those who consumed the higher dose formulation than those who consumed the lower dose one.

It was concluded that higher doses of bacterial cells in probiotic formulations may allow for a higher, earlier and longer recovery time suggesting that higher doses may lead to an earlier and more stable transient colonization.

“Higher doses of probiotics result in higher levels of fecal recovery; this has been shown before.

What is fascinating with the Taverniti study is they show a higher dose also leads to an earlier and longer detection of the consumed probiotics; suggesting a more stable ‘colonization’.

This begs the question if a higher probiotic dose also leads to earlier and more reliable health benefits,” said Arthur Ouwehand, Ph.D., Technical Fellow, DuPont Nutrition & Health.

ADVERT

The study involved 40 healthy adults of both genders aged between 18 and 60.

It was published in the journal Nutrients (Taverniti et al. Nutrients 11(2):285, 2019).

“Since we are experiencing a clear trend toward multi-strain and higher potency probiotic formulations in many markets around the world, it is encouraging to see study results which may assist in better understanding the benefits of these formulations from a consumer perspective,” said Valerie Delahaye, Global Leader of Dietary Supplements for DuPont Nutrition & Health.

Other Posts Worth Reading

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.